Diabetic Nephropathy Pipeline Report, H1 2019 – Therapeutic Review of 39 Companies & Drug Profiles – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Diabetic Nephropathy – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Diabetic Nephropathy – Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 19, 14, 27 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).
• The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

• Allist Shanghai Pharmaceutical Technology Co Ltd
• Antisense Therapeutics Ltd
• Araim Pharmaceuticals Inc
• Astellas Pharma Inc
• Bayer AG
• Betagenon AB
• Bird Rock Bio Inc
• BLR Bio LLC
• Boehringer Ingelheim GmbH
• CCRP Therapeutics GmbH
• Cellmid Ltd
• Certa Therapeutics Pty Ltd
• ChemoCentryx Inc
• CSL Ltd
• Daiichi Sankyo Co Ltd
• Dimerix Bioscience Pty Ltd
• GenKyoTex SA
• Gilead Sciences Inc
• GNI Group Ltd
• Inspyr Therapeutics Inc
• Johnson & Johnson
• MediPost Co Ltd
• Merck & Co Inc
• Mesoblast Ltd
• Mitsubishi Tanabe Pharma Corp
• Novartis AG
• Novo Nordisk AS
• Noxxon Pharma AG
• Paranta Biosciences Ltd
• PhytoHealth Corp
• ProMetic Life Sciences Inc
• Reata Pharmaceuticals Inc
• Redx Pharma Plc
• Sarfez Pharmaceuticals Inc
• Serodus ASA
• Teijin Pharma Ltd
• Theravance Biopharma Inc
• Twoxar Inc
• Ube Industries Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ikbowa

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics: Liver and Kidney Disorders Drugs, Endocrine and Metabolic Disorders Drugs